MitoTEMPOL Inhibits ROS-Induced Retinal Vascularization Pattern by Modulating Autophagy and Apoptosis in Rat-Injected...

Area of Science:

• Biomedical Science
• Ophthalmology
• Endocrinology

Background:

• Diabetic retinopathy (DR) is a leading cause of blindness in adults with diabetes, characterized by retinal malfunction.
• High blood glucose levels in diabetes elevate reactive oxygen species (ROS), contributing to DR pathogenesis.
• ROS modulators, like MitoTEMPOL, present a potential therapeutic strategy for DR.

Purpose of the Study:

• To investigate the effects of MitoTEMPOL on ROS balance in a rat model of diabetic retinopathy.
• To explore the correlation between MitoTEMPOL treatment, retinal vascularization, autophagy, and apoptosis in diabetic rats.

Main Methods:

• A streptozotocin-induced diabetic rat model was used, with four experimental groups: control, TEMPOL, diabetic, and diabetic + TEMPOL.
• Rats were treated with MitoTEMPOL for five weeks.
• Retinal vascularization, gene expression (superoxide dismutase), and protein levels (caspase 3, 9, protein carbonyl) were analyzed.

Main Results:

• MitoTEMPOL treatment reduced retinal vascularization and decreased markers of oxidative stress and apoptosis (superoxide dismutase, protein carbonyl, caspase 3, and caspase 9).
• Diabetic rats exhibited altered autophagy, which was reversed by MitoTEMPOL treatment.
• MitoTEMPOL modulated autophagy and apoptosis in the diabetic rat retina.

Conclusions:

• MitoTEMPOL acts as a potent antioxidant, inhibiting ROS-induced retinal vascularization patterns in diabetic retinopathy.
• MitoTEMPOL's modulation of autophagy and apoptosis contributes to its protective effects against diabetic retinopathy.
• This study supports MitoTEMPOL as a potential therapeutic agent for preventing diabetic retinopathy.